Novacta Therapeutics and O2h Announce a Multi FTE Medicinal Chemistry Collaboration
News Dec 18, 2009
Novacta Therapeutics and O2h announced a multi FTE chemistry collaboration to support their internal drug discovery efforts. This is the third successive collaboration over the last three years.
“Following two very successful projects, we are excited to enter a third collaboration that combines the strengths of both companies.” said Dr. Sjoerd Wadman, Head of Chemistry at Novacta Therapeutics.
Sunil Shah, CEO of O2h said “We are excited to be a part of and support the research programs that Novacta is pioneering in the area of Lantibiotics and Bacteriocins. The large investment that they have received to date is testament to the scientific breakthroughs that they have made in this area”.
Protein "Intentionally" Terminates own Synthesis by Destabilizing Synthesis Machinery — the RibosomeNews
A research group has discovered that a protein, during its synthesis, may destabilize the structure of the ribosome and end its own synthesis prematurely, and found that this phenomenon is used for adapting the cell to its environment.READ MORE
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE